Mammoth Biosciences

Mammoth Biosciences is a biotechnology company founded in 2017 with the goal of leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies and decentralized precision diagnostics. Co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, along with Trevor Martin, Janice Chen, and Lucas Harrington, the company's ultracompact proteins are designed to enable in vivo gene editing in difficult-to-reach tissues utilizing various editing modalities. Mammoth Biosciences has secured a $150.00M Series D investment in September 2021 from a group of notable investors including NFX, Mayfield, Plum Alley Investments, Redmile Group, Decheng Capital, Foresite Capital, Senator Investment Group, Sixth Street Growth, Tachyon Ventures, and Bradley Horowitz. The company has also established partnerships with leading pharmaceutical and biotechnology entities to expand the reach of its innovative technology. Mammoth's strong emphasis on deep science, industry experience, and robust intellectual property portfolio positions it to achieve its mission of transforming the lives of patients and unlocking the full potential of CRISPR technologies. The company's commitment to pioneering biotechnological advancements signifies a promising trajectory within the biotechnology sector.